A PHASE II TRIAL OF ERLOTINIB VERSUS PEMETREXED AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH ADVANCED EGFR WILD-TYPE AND EGFR FISH-POSITIVE LUNG ADENOCARCINOMA
JOURNAL OF THORACIC ONCOLOGY（2013）
Key words
non-small cell lung cancer,second-line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined